Olaparib Induces RPL5/RPL11-Dependent p53 Activation via Nucleolar Stress

Olaparib Induces RPL5/RPL11-Dependent p53 Activation via Nucleolar Stress

The poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi) Olaparib is a widely used targeted therapy for a variety of solid tumors with homologous recombination deficiency (HRD) caused by mutation of BRCA1/2 or other DNA repair genes. The anti-tumor activity of Olaparib has been largely attributed t...

Full description

Bibliographic Details
Main Authors: Tao Han, Jing Tong, Mengxin Wang, Yu Gan, Bo Gao, Jiaxiang Chen, Youxun Liu, Qian Hao, Xiang Zhou
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-06-01
Series:Frontiers in Oncology
Subjects:
p53
ribosomal protein (RP)
nucleolar (ribosomal) stress
MDM2
PARP inhibitior
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.821366/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.821366/full

Similar Items